Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Jan Nilsson

Professor

Default user image.

Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease

Author

  • Gunilla Nordin Fredrikson
  • Bo Hedblad
  • Göran Berglund
  • Ragnar Alm
  • Jan-Åke Nilsson
  • Alexandru Schiopu
  • Prediman K Shah
  • Jan Nilsson

Summary, in English

Background and Purpose - Autoantibodies against antigens in oxidized low-density lipoprotein are common in people; experimental studies suggest that these immune responses have a functional role in the disease process. The aim of this study was to evaluate the relationship between the immune response against one defined oxidized low-density lipoprotein antigen, the aldehyde-modified peptide corresponding amino acids 3136 and 3155 (MDA-p210) in apolipoprotein (apo) B-100, and progression of carotid intima media thickness (IMT). Methods - IgM and IgG against MDA-p210 were determined by enzyme-linked immunosorbent assay at baseline and after 12 months of treatment with placebo, metoprolol, fluvastatin, or metoprolol/ fluvastatin in 751 individuals participating in the BCAPS. Carotid IMT was assessed by ultrasonography at baseline and after 18 and 36 months of treatment. Results - Antibody levels did not change in response to treatment, but high baseline MDA-p210 IgM levels were associated with a more rapid progression of carotid disease both at 18 ( r = 0.09, P < 0.05) and 36 months ( r = 0.12, P < 0.005). At 36 months, the difference in IMT progression rate per year between those with high MDA-p210 IgM levels and those with low was 0.011 mm ( 95% CI = 0.005 to 0.018 mm, P < 0.0001). Treatment with fluvastatin markedly decreased the progression of IMT among subjects with high but not with low MDA-p210 IgM levels. There was no association between MDA-p210 IgG and carotid IMT progression. Conclusions - IgM against the aldehyde-modified peptide corresponding amino acids 3136 and 3155 in apo B-100 is common in subjects with asymptomatic carotid disease, and high levels are associated with a more rapid progression of carotid IMT. The observation that the effect of fluvastatin was restricted to subjects with high MDA-p210 IgM levels may reflect the increased rate of disease progression in this group.

Department/s

  • Cardiovascular Research - Immunity and Atherosclerosis
  • Cardiovascular Research - Epidemiology
  • Internal Medicine - Epidemiology
  • Orthopedics - Clinical and Molecular Osteoporosis Research
  • Joint and Soft Tissue Unit

Publishing year

2007

Language

English

Pages

1495-1500

Publication/Series

Stroke: a journal of cerebral circulation

Volume

38

Issue

5

Document type

Journal article

Publisher

American Heart Association

Topic

  • Neurology

Keywords

  • carotid arteries
  • atherosclerosis
  • echocardiography
  • lipoproteins
  • immune system

Status

Published

Research group

  • Cardiovascular Research - Immunity and Atherosclerosis
  • Cardiovascular Research - Epidemiology
  • Internal Medicine - Epidemiology
  • Orthopedics - Clinical and Molecular Osteoporosis Research
  • Joint and Soft Tissue Unit

ISBN/ISSN/Other

  • ISSN: 1524-4628